| Literature DB >> 23698042 |
Shuo Xu1, Ming-Ying Shang, Guang-Xue Liu, Feng Xu, Xuan Wang, Cheng-Chao Shou, Shao-Qing Cai.
Abstract
Six new phenolic compounds, named smiglabrone A (1), smiglabrone B (2), smilachromanone (3), smiglastilbene (4), smiglactone (5), smiglabrol (6), together with fifty-seven known ones 7-63 were isolated from the rhizomes of Smilax glabra. Their structures were elucidated on the basis of extensive spectroscopic analyses, as well as by comparison with literature data. Twenty-seven of these compounds were obtained from and identified in the genus Smilax for the first time. The absolute configuration of (2S)-1,2-O-di-trans-p-coumaroylglycerol (43) was determined for the first time using the exciton-coupled circular dichroism (ECCD) method. Thirty isolated compounds were evaluated for their antimicrobial activity against three Gram-negative bacteria, three Gram-positive bacteria and one fungus, and the corresponding structure-activity relationships were also discussed. Eighteen compounds were found to be antimicrobial against the microorganisms tested and the minimum inhibitory concentrations (MIC) were in the range of 0.0794-3.09 mM. Among them, compound 1 showed antimicrobial activity against Canidia albicans with MIC value of 0.146 mM, which was stronger than cinchonain Ia with an MIC of 0.332 mM. Compounds 3 and 4 exhibited inhibitory activity against Staphylococcus aureus with MIC values of 0.303 and 0.205 mM, respectively. The results indicated that these antimicrobial constituents of this crude drug might be responsible for its clinical antimicrobial effect.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23698042 PMCID: PMC6270451 DOI: 10.3390/molecules18055265
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Chemical structures of compounds 1–6.
Figure 2Chemical structures of compounds 7–23, 28–45, 49–52 and 62.
1H-NMR (600 MHz) and 13C-NMR (150 MHz) spectra data of compounds 1 and 2 (in CD3OD, J in Hz, δ in ppm).
| Position | 1 | 2 | ||
|---|---|---|---|---|
|
|
| |||
| 2 | 4.81 (1H, s) | 79.8 | 4.82 (1H, s) | 79.8 |
| 3 | 4.26 (1H, m) | 66.8 | 4.25 (1H, m) | 66.7 |
| 4 | 2.85 (1H, dd,
| 29.8 | 2.85 (1H, dd,
| 29.7 |
| 2.92 (1H, dd,
| 2.92 (1H, dd,
| |||
| 5 | – | 157.4 | – | 157.4 |
| 6 | 6.20 (1H, s) | 96.3 | 6.19 (1H, s) | 96.3 |
| 7 | – | 151.6 | – | 151.7 |
| 8 | – | 106.2 | – | 106.2 |
| 9 | – | 153.6 | – | 153.5 |
| 10 | – | 105.4 | – | 105.3 |
| 1′ | – | 132.0 | – | 132.0 |
| 2′ | 7.06 (1H, d,
| 115.1 | 7.03 (1H, d,
| 115.1 |
| 3′ | – | 146.2 | – | 146.1 |
| 4′ | – | 145.9 | – | 145.8 |
| 5′ | 6.79 (1H, d,
| 116.1 | 6.781 (1H, d,
| 116.0 |
| 6′ | 6.84 (1H, dd,
| 119.1 | 6.83 (1H, dd,
| 119.1 |
| 1′′ | – | 135.2 | – | 135.8 |
| 2′′ | 6.43 (1H, s) | 105.0 | 6.776 (1H, d,
| 112.2 |
| 3′′ | – | 149.2 | – | 148.8 |
| 4′′ | – | 135.1 | – | 146.3 |
| 5′′ | – | 149.2 | 6.62 (1H, d,
| 116.2 |
| 6′′ | 6.43 (1H, s) | 105.0 | 6.50 (1H, dd,
| 119.4 |
| 7′′ | 4.60 (1H, br. d,
| 36.2 | 4.60 (1H, br. d,
| 35.7 |
| 8′′ | 2.91 (1H, dd,
| 37.5 | 2.90 (1H, dd,
| 37.8 |
| 3.12 (1H, dd,
| 3.10 (1H, dd,
| |||
| 9′′ | – | 171.0 | – | 170.9 |
| 3′′-OCH3 | – | – | 3.56 (3H, s) | 56.0 |
| 3′′, 5′′-OCH3 | 3.59 (6H, s) | 56.4 | – | – |
Figure 3Main HMBC correlations of compounds 1, 3–6.
1H-NMR (500 MHz) and 13C-NMR (125 MHz) spectra data of compound 3 (in CD3OD, J in Hz, δ in ppm).
| Position |
| |
|---|---|---|
| 2 | 4.06 (1H, d,
| 72.9 |
| 3.96 (1H, d,
| – | |
| 3 | – | 73.6 |
| 4 | – | 200.6 |
| 5 | – | 161.6 |
| 6 | – | 106.7 |
| 7 | – | 167.5 |
| 8 | 6.14 (1H, s) | 91.8 |
| 9 | – | 162.7 |
| 10 | – | 101.8 |
| 11 | 2.90 (1H, d,
| 40.8 |
| 2.86 (1H, d,
| – | |
| 1′ | – | 126.8 |
| 2′, 6′ | 7.05 (2H, d,
| 132.8 |
| 3′, 5′ | 6.70 (2H, d,
| 115.9 |
| 4′ | – | 157.5 |
| 7-OCH3 | 3.86 (3H, s) | 56.5 |
| 6-CH3 | 1.95 (3H, s) | 7.0 |
1H-NMR (600 MHz) and 13C-NMR (150 MHz) spectra data of compound 4 (in CD3OD, J in Hz, δ in ppm).
| Position |
| |
|---|---|---|
| 1 | – | 126.0 |
| 2 | – | 144.6 |
| 3 | – | 146.5 |
| 4 | 6.69 (1H, dd,
| 114.9 |
| 5 | 6.66 (1H, t,
| 120.5 |
| 6 | 7.02 (1H, dd,
| 118.3 |
| 7 | 6.96 (1H, d,
| 129.5 |
| 8 | 7.37 (1H, d,
| 124.7 |
| 1′ | – | 141.6 |
| 2′, 6′ | 6.48 (2H, d,
| 105.9 |
| 3′, 5′ | – | 159.7 |
| 4′ | 6.17 (1H, t,
| 102.8 |
1H-NMR (600 MHz) and 13C-NMR (150 MHz) spectra data of compound 5 (in CD3OD, J in Hz, δ in ppm).
| Position |
| |
|---|---|---|
| 1 | – | 179.6 |
| 2 | 2.65 (2H, m) | 33.8 |
| 3 | 2.75 (1H, m) | 49.5 |
| 4 | 5.72 (1H, d,
| 85.1 |
| 5 | – | 136.3 |
| 6 | – | 128.9 |
| 7 | 6.85 (1H, d,
| 130.7 |
| 8 | 6.69 (1H, d,
| 116.2 |
| 9 | – | 156.2 |
| 10 | – | 125.2 |
| 11 | 1.76 (1H, m) | 31.3 |
| 12 | 0.76 (3H, d,
| 21.9 |
| 13 | 0.98 (3H, d,
| 19.9 |
| 14 | 2.30 (3H, s) | 20.8 |
| 15 | 2.22 (3H, s) | 13.0 |
1H-NMR (600 MHz) and 13C-NMR (150 MHz) spectra data of compound 6 (in C5D5N, J in Hz, δ in ppm).
| Position |
| |
|---|---|---|
| 1, 3 | – | 159.7 |
| 2 | 6.88 (1H, t,
| 102.9 |
| 4, 6 | 6.97 (2H, d,
| 107.1 |
| 5 | – | 145.4 |
| 7 | 5.13 (1H, d,
| 78.7 |
| 8 | 4.56 (1H, d,
| 89.5 |
| 9 | – | 130.0 |
| 10, 14 | 7.30 (2H, d,
| 129.9 |
| 11, 13 | 7.06 (2H, d,
| 115.7 |
| 12 | – | 158.4 |
| 1, 3-OH | 11.24 (2H, br. s) | – |
| 7-OH | 3.59 (1H, br. s) | – |
| 8-OCH3 | 3.28 (3H, s) | 56.7 |
| 12-OH | 11.38 (1H, br. s) | – |
Figure 4CD and UV spectra of compound 43.
Minimum inhibitory concentrations (MICs, mM) of the selected compounds obtained from the rhizomes of S. glabra.
| Compound | EC | PA | KP | MRSA | SA | EF | CA |
|---|---|---|---|---|---|---|---|
|
| 0.604 | 0.604 | 0.604 | 0.302 | 0.302 | 0.302 | 0.146 |
|
| >1.21 | >1.21 | >1.21 | 0.605 | 0.303 | 0.605 | 0.605 |
|
| 1.64 | 1.64 | 1.64 | 0.409 | 0.205 | 0.819 | 0.819 |
|
| >2.10 | >2.10 | >2.10 | 2.10 | 2.10 | >2.10 | >2.10 |
|
| >2.10 | >2.10 | >2.10 | 0.524 | 0.524 | 1.05 | >2.10 |
|
| >1.33 | >1.33 | >1.33 | >1.33 | >1.33 | >1.33 | >1.33 |
|
| >1.33 | >1.33 | >1.33 | >1.33 | >1.33 | >1.33 | 0.666 |
|
| >1.33 | >1.33 | >1.33 | 1.33 | >1.33 | >1.33 | >1.33 |
|
| 1.33 | 1.33 | 1.33 | 1.33 | 0.666 | 1.33 | 1.33 |
|
| >1.38 | >1.38 | >1.38 | >1.38 | >1.38 | >1.38 | >1.38 |
|
| >1.33 | >1.33 | >1.33 | >1.33 | >1.33 | >1.33 | >1.33 |
|
| >1.33 | >1.33 | >1.33 | 1.33 | 1.33 | 1.33 | >1.33 |
|
| >2.07 | >2.07 | >2.07 | 1.03 | 0.517 | 1.03 | >2.07 |
|
| >1.33 | 0.663 | >1.33 | 0.0801 | 0.0801 | 0.160 | 0.160 |
|
| >0.880 | >0.880 | >0.880 | >0.880 | >0.880 | >0.880 | >0.880 |
|
| 0.663 | 0.663 | 0.663 | 1.33 | 0.663 | 1.33 | 0.332 |
|
| >2.63 | >2.63 | >2.63 | 0.159 | 0.0794 | 0.159 | 0.657 |
|
| >1.54 | >1.54 | >1.54 | 0.768 | 0.768 | 1.54 | >1.54 |
|
| 1.64 | 1.64 | 1.64 | 0.409 | 0.205 | >1.64 | 0.819 |
|
| 2.52 | 2.52 | 2.52 | 0.630 | 0.630 | 1.26 | 0.630 |
|
| 3.09 | 3.09 | 3.09 | 3.09 | 1.55 | 3.09 | 3.09 |
|
| >2.60 | >2.60 | >2.60 | >2.60 | >2.60 | >2.60 | >2.60 |
| Cipro | 0.00302 | 0.00302 | 0.00604 | ||||
| Van | 0.000690 | 0.000690 | 0.00138 | ||||
| Keto | 0.0000301 |
EC, Escherichia coli; PA, Pseudomonas aeruginosa PA01; KP, Kiebsiella pneumonia (clinical isolate); MRSA, methicillin-resistant Staphylococcus aureus (clinical isolate); SA, Staphylococcus aureus ATCC6538; EF, Enterococcus faecalis; CA, Canidia albicans SC5314; Cipro, ciprofloxacin; Van, vancomycin; Keto, ketoconazole.